1. Home
  2. HURA vs ESGL Comparison

HURA vs ESGL Comparison

Compare HURA & ESGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HURA
  • ESGL
  • Stock Information
  • Founded
  • HURA 2009
  • ESGL 1999
  • Country
  • HURA United States
  • ESGL Singapore
  • Employees
  • HURA N/A
  • ESGL N/A
  • Industry
  • HURA
  • ESGL
  • Sector
  • HURA
  • ESGL
  • Exchange
  • HURA Nasdaq
  • ESGL Nasdaq
  • Market Cap
  • HURA 122.0M
  • ESGL 114.6M
  • IPO Year
  • HURA N/A
  • ESGL N/A
  • Fundamental
  • Price
  • HURA $3.06
  • ESGL $2.73
  • Analyst Decision
  • HURA Strong Buy
  • ESGL
  • Analyst Count
  • HURA 2
  • ESGL 0
  • Target Price
  • HURA $11.50
  • ESGL N/A
  • AVG Volume (30 Days)
  • HURA 773.7K
  • ESGL 24.7K
  • Earning Date
  • HURA 08-14-2025
  • ESGL 09-03-2025
  • Dividend Yield
  • HURA N/A
  • ESGL N/A
  • EPS Growth
  • HURA N/A
  • ESGL N/A
  • EPS
  • HURA N/A
  • ESGL N/A
  • Revenue
  • HURA N/A
  • ESGL $6,099,784.00
  • Revenue This Year
  • HURA N/A
  • ESGL N/A
  • Revenue Next Year
  • HURA N/A
  • ESGL N/A
  • P/E Ratio
  • HURA N/A
  • ESGL N/A
  • Revenue Growth
  • HURA N/A
  • ESGL N/A
  • 52 Week Low
  • HURA $1.80
  • ESGL $0.90
  • 52 Week High
  • HURA $8.63
  • ESGL $3.87
  • Technical
  • Relative Strength Index (RSI)
  • HURA N/A
  • ESGL 43.22
  • Support Level
  • HURA N/A
  • ESGL $2.45
  • Resistance Level
  • HURA N/A
  • ESGL $2.80
  • Average True Range (ATR)
  • HURA 0.00
  • ESGL 0.24
  • MACD
  • HURA 0.00
  • ESGL -0.02
  • Stochastic Oscillator
  • HURA 0.00
  • ESGL 51.35

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

About ESGL ESGL Holdings Limited

ESGL Holdings Ltd is a waste management, treatment, and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical, and electroplating companies.

Share on Social Networks: